Cart
sales@molnova.com
Amatuximab
CAS No. 931402-35-6
Amatuximab( —— )
Catalog No. M36657 CAS No. 931402-35-6
Amatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 511 | In Stock |
|
| 10MG | 820 | In Stock |
|
| 25MG | 1226 | In Stock |
|
| 50MG | 1637 | In Stock |
|
| 100MG | 2213 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAmatuximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.
-
DescriptionAmatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number931402-35-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hassan R, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927-5936. ?
molnova catalog
related products
-
Protogracillin
Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW) which may inhibit platelet aggregation (PAG) and thrombosis. Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action.
-
NFATc1-IN-1
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM.
-
Ardisiacrispin B
Ardisiacrispin B displays cytotoxic effects in multi-factorial drug resistant cancer cells via ferroptotic and apoptotic cell death.
